When someone suffers a serious burn, healing can be a long and difficult journey. Severe burns damage not only the outer layer of skin but also deeper tissues that help protect the body from infection and fluid loss.
Recovery often requires intensive medical care, repeated dressing changes, surgeries, and months of rehabilitation.
Despite advances in modern medicine, treating burns remains a major challenge. Doctors frequently use skin grafts, which involve taking healthy skin from one area of the body and placing it over the damaged region.
Although effective, skin grafts have important limitations. Patients must heal from both the burn and the skin removal site. In cases involving large burns, there may not be enough healthy skin available for transplantation.
Researchers have long searched for alternatives that could help the body repair itself more effectively. A new study from scientists at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine may bring that goal closer to reality.
The study, published in Biomaterials, focused on a medication called 4-aminopyridine, or 4-AP. Most people know this drug for a completely different purpose.
Doctors commonly prescribe it to some patients with multiple sclerosis to improve nerve signaling and walking ability. Because the medication has already been approved for medical use, researchers have a good understanding of its safety and side effects.
Several years ago, scientists noticed that 4-AP appeared to influence skin cells involved in wound repair. This observation raised an intriguing question: Could the drug help burn wounds heal faster? Unfortunately, taking the medication throughout the body for long periods could create serious side effects, including seizures.
Instead of abandoning the idea, the researchers developed a new way to deliver the drug. They embedded it inside a soft gel made from biocompatible materials. The gel can be applied directly to the wound surface, allowing the medication to remain concentrated at the injury site.
This strategy offers a major advantage. Because the drug stays largely within the wound area, exposure to the rest of the body is greatly reduced. This may lower the risk of harmful side effects while preserving the drug’s healing properties.
Laboratory testing showed that the gel steadily released the medication over time and supported healthy cell growth. The treatment appeared to create an environment that encouraged tissue repair. In laboratory wound models, more than 90% wound closure was achieved within two days.
The researchers then moved on to animal studies. The differences between treated and untreated wounds became increasingly obvious as healing progressed. By the sixth day, treated wounds were already closing faster. After three weeks, wounds receiving the gel had nearly completely healed, while untreated wounds still showed significant open areas.
The scientists investigated what was happening beneath the surface. They found that the gel reduced excessive inflammation, a process that can slow healing when it persists too long. The treatment also stimulated the formation of new skin tissue and increased the growth of blood vessels needed to supply oxygen and nutrients.
Another important finding involved collagen. Skin relies on collagen for strength, flexibility, and structure. The treated wounds produced substantially more collagen than untreated wounds. The balance of different collagen types also suggested that the repaired tissue was maturing in a healthier way.
These findings suggest that the gel is not simply helping wounds close more quickly. It may also improve the quality of healing itself. Faster closure combined with stronger tissue development could eventually reduce complications and improve long-term outcomes for burn survivors.
One reason this research is generating excitement is that it builds upon an existing medicine. Drug development often takes many years and costs enormous amounts of money. By repurposing a medication that has already undergone extensive safety testing, researchers may be able to shorten the path toward human studies.
The investigators stress that the treatment is still in the research phase. Human clinical trials are needed before doctors can determine whether the gel is safe and effective for patients. Even so, the early results provide encouraging evidence that a relatively simple treatment could one day transform burn care.
If you care about skin health, please read studies about top signs of diabetic skin disease, and Mediterranean diet could help lower the skin cancer risk.
For more health information, please see recent studies about eating fish linked to higher risk of skin cancer, and results showing how to combat the effects of aging on your skin.
Source: University of Arizona College of Medicine and Terasaki Institute for Biomedical Innovation.
